Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ARQ 501 + gemcitabine in unresectable pancreatic adenocarcinoma
2006-001358-29Phase 2Completed
- Sponsor
- ArQule
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lapachone in pancreatic adenocarcinoma (PDAC), sponsored by ArQule. Primary endpoint: overall response rate. Started Jan 2007; status: completed.
02
Drugs
lapachone
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2006-001358-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001358-29.